Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies
By Don Nico Forbes
Shares in Zentalis Pharmaceuticals rose after the company said the U.S. Food and Drug Administration lifted a partial clinical halt on studies of its cancer treatment azenosertib.
Shares were up 41% in premarket trading at $4.57.
The company said Monday that the regulator cleared the drug's enrollment in all continuing clinical studies, with no changes to its clinical development plan.
Azenosertib is an orally-ingested inhibitor of WEE1--a protein linked with various forms of cancer--currently being tested in monotherapy and combination clinical studies for ovarian cancer and additional tumor types.
Zentalis said it remains on track to meet all previously-disclosed data guidance for 2024, and that it will present data for azenosertib as a monotherapy later this year.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
September 16, 2024 07:52 ET (11:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States